Microbiota-Associated Amino Acid Metabolites in Inflammatory Bowel Disease: Emerging Key Players in the Host–Microbe Interface

What To Know

This is a review article summarizing recent clinical metabolomic and mechanistic studies that link amino-acid-derived microbial metabolites (for example, tryptophan-derived indoles, branched-chain amino acids, arginine–polyamine products, glutamate, histidine) to intestinal barrier function, immune signaling, and mucosal repair in IBD.

The authors report consistent patterns across cohorts—some metabolites (e.g., tryptophan indoles, glutamate, histidine, select BCAAs) are often reduced in IBD samples, while others (e.g., serine, proline, some polyamine degradation products) are frequently elevated or associated with active disease or therapy response.

The review highlights limitations: it does not establish causality for most metabolites, and it emphasizes gaps such as metabolite origin (host vs microbe), spatial distribution in the gut, and functional validation.

The authors discuss potential near-term uses for metabolite signatures as biomarkers and longer-term possibilities for precision interventions targeting metabolic pathways.